



WORLD
DIABETES
FOUNDATION



Presents

Global Diabetes Walk

FINANCIAL STATEMENTS FOR 2022

APPROVED BY THE BOARD OF DIRECTORS 16 MARCH 2023

CVR-nr. 26 56 17 79

Krogshøjvej 30A · DK-2880 Bagsværd

Education to protect tomorrow

12th Nov. 2022 | 8am

SCENE BY TOSOKE


INTRO

Vision, mission and strategy

WDF's vision is to alleviate human suffering related to diabetes among those in greatest need. WDF's mission is:

- We create partnerships to assist people with diabetes and those at risk, acting as a catalyst to help others do more
- We link people and resources to educate and advocate globally and provide care locally
- Our priority is to support the poorest of the poor
- We empower local communities to achieve sustainable solutions and yield replicable models
- We encourage innovative strategies to prevent diabetes and its consequences

WDF's work is divided into two intervention areas - Care and Primary Prevention - supported by Advocacy. It is governed by three guiding principles: integrated care, life-course approach, and universal health coverage.



INTRO



Meeting with partners in Bangladesh.

Partnerships as building blocks

Partnerships are key to WDF's work. Projects supported at country level are initiated, implemented and sustained through local partners. WDF has supported partners in more than 100 countries and at all levels – from grassroots organisations to national, regional and global entities.

In many countries, the financial and technical support provided by WDF has spanned over many years, often starting with small initiatives and developing into more broad-based country programmes or larger-scale national responses.

We value meeting our partners and beneficiaries in their local environments, listening and providing technical sparring and exchange.

Our project portfolio

To date, the World Diabetes Foundation has supported 595 projects in 119 countries. 131 of these are ongoing projects. For every euro provided by WDF, project partners raise approximately 2 euros in cash or in-kind contributions from other sources.

Project proposals are formulated and owned locally. Projects should provide focused, replicable and sustainable solutions with the potential to prevent diabetes and improve the lives of people with the condition.

During the 2022 financial year, 13 new projects were approved by the Board of Directors.

Increasing support for national programmes

The grants awarded in recent years represent a shift in WDF's strategy, with increasing support for national programmes in countries where partnerships have matured, and where a strong collaboration with the government and leading national stakeholders is in place.

A partnership model developed in Tanzania has proven effective at providing larger-scale support for national responses with focus on diabetes and hypertension. Additional large-grant WDF partnerships have been developed and launched in other countries.

In Jordan, WDF is supporting an integrated NCD-humanitarian national response strategy with focus on prevention and access to care for both refugee populations and host communities. Building on the learnings from the programme in Jordan, a similar large-scale project has been launched in Lebanon.

Another example of current large-scale interventions is the joint collaboration with the Novo Nordisk Foundation and the Novo Nordisk A/S on the Changing Diabetes in Children programme, which further integrates type 1 diabetes care into health systems in eight countries - six in Eastern Africa and two in the Middle East - based on the existing WDF partnership framework in each country.

By scaling up its grants, WDF is not only able to elevate and expand current partnerships, it can also engage with and leverage investments of other major donors in the wider health and development space.

2022 HIGHLIGHTS



WDF20 celebration in Denmark.

WDF marks 20 years of improving lives – together

In 2022, WDF celebrated its 20th anniversary. WDF marked the occasion with various activities during the year, each showcasing WDF's long-term partnerships worldwide and their positive and sustainable impact on health systems and on people living with diabetes in low- and middle-income countries (LMICs).

An anniversary website – [WDF20.org](https://www.wdf20.org) – captured highlights from two decades of WDF partnerships, portraying WDF's development from its first container clinic in Tanzania to funder of more than 500 partnerships in 119 countries worldwide.

The celebration also included a virtual conference for WDF partners, and a 'Diabetes Champions' campaign that recognised WDF partners who are leading the global fight against diabetes. The celebration culminated in December with a WDF symposium, '20 Years of Partnership to Improve Diabetes Care and Prevention', at the International Diabetes Federation (IDF) World Diabetes Congress in Lisbon, Portugal.

UNHCR collaboration brings care to refugees and host communities

Many refugees face serious obstacles in meeting their health needs. Forced displacement often disrupts the treatment of NCDs or delays the diagnosis, with potentially severe consequences for individuals and their families.

In response, WDF and United Nations High Commissioner for Refugees (UNHCR) in 2022 initiated an ambitious new partnership to support a systematic integration of NCD prevention and control into the humanitarian response.

A three-year joint project will be implemented in Tanzania, Burundi, and Sudan. Up to one million refugees, returnees and internally displaced people, and at least 500,000 people from the host communities, will receive improved NCD care. The project will build capacity of local health facilities, train primary health care professionals and community health workers and provide essential equipment and supplies. NCD awareness raising, assessments and screening for risk factors will also take place.

At the global level, efforts to integrate NCDs into health programming will be strengthened across the UNHCR organisation and in its many implementing partners worldwide. The partnership has a total value of 43.8 million DKK (6.8 million USD) and is partly supported through a grant from the Novo Nordisk Foundation to WDF.

Maternity Foundation partnership approved

In 2022, the WDF Board approved a new partnership with the Maternity Foundation supporting ongoing efforts by the Government of India to strengthen antenatal and gestational diabetes care for pregnant women and new mothers in Jharkand State.

2022 HIGHLIGHTS

The project will use Maternity Foundation's global digital tool, the Safe Delivery App, which has more than 150,000 downloads in India alone. The application is a training and learning tool for midwives and other healthcare workers, providing guidance on how to handle the most common complications related to pregnancy and childbirth.

New clinical content on antenatal care and gestational diabetes will be developed in English and Hindi and published in the app. The project will also train more than 1,500 healthcare workers and students, and the app's new clinical content will be included in the curriculum for nurses by 2024.

The project is an example of WDF's approach to Primary Prevention. WDF's Primary Prevention partnerships promote healthy environments with a focus on childhood, adolescence, and a woman's reproductive years.

Leveraging lessons from the HIV response in NCDs

Reaching people living in remote and scattered rural communities with health information and services often poses a challenge in chronic disease management. In Sub-Saharan Africa, decades of successful HIV responses have innovated effective new ways to reach communities at risk. Diabetes prevention, diagnosis and care can draw many valuable lessons from the HIV response.

In December 2022, the WDF Board approved a grant to the 'Scale up diabetes awareness, prevention and management' project in the Kingdom of Eswatini. WDF, the Clinton Health Access Initiative and the Ministry of Health Eswatini will pursue integration of diabetes services within the existing health care system, leveraging lessons from the HIV response.

The national, 3-year diabetes project builds on the support that WDF has provided to Eswatini since 2018 through partnerships with Population Services International and Good Shepherd Hospital.

It aims to decentralise NCD care to the primary care level; shift tasks to nurses and rural health motivators; provide differentiated delivery of diabetes services to patients; establish HIV/NCD guidelines and collaborations to strengthen integration and implementation; and – importantly – ensure that people can live healthier lives through the development of a public food procurement policy.

A philanthropic initiative is re-launched

In January, WDF re-launched the Partner 2 Partner Academy (P2P Academy). The programme was introduced in 2007 to provide clinical training for health staff in WDF partner organisations. With the launch of its new phase, WDF seeks to broaden the scope of the Academy to focus on general capacity building and strengthening connections among WDF's growing community of partners.

The new P2P Academy supports partners with small-scale, flexible and targeted interventions. The programme has been granted 5 million DKK for a period of four years and will address five areas: clinical and organisational capacity building; networking; field work for MA thesis research at the University of Copenhagen; and piloting of experimental and innovative project approaches.

In 2022, the P2P Academy webinar series was introduced to further support engagement with and between WDF's partners. The webinars provide a platform for learning and knowledge sharing within topics of common interest. The focus is on practical and implementation levels of diabetes care, prevention and advocacy for those stakeholders who are present on the ground in the LMIC context.

Global Diabetes Walk returns to larger outdoor events

The Global Diabetes Walk campaign rerouted itself during the COVID-19 pandemic, encouraging people to walk however they could – with a few friends, alone, or even inside. 2022 marked a return to the campaign's traditional focus on larger outdoor events.

In July, the campaign welcomed 2022 Walk organisers with several changes. The 2022 campaign also introduced a new concept – the Walk Ambassador – organisations that pledged to organise their own Walks and provide guidance to others.

The result was 285 Walks in 84 countries, attracting more than 78,000 participants. Together, one step at a time, they spread World Diabetes Day messages and maintained the tradition and spirit of the 18-year-old Global Diabetes Walk campaign.

Global Diabetes Walks in 2022 ranged from 1 to 15,000 participants and included many picturesque and unique routes. WDF's partners were again a powerful force, organising 40 Walks with more than 42,000 participants.



MANAGEMENT REVIEW 2022

FINANCIAL HIGHLIGHTS

Novo Nordisk A/S Donation

In 2022, donations from Novo Nordisk A/S totalling DKK 93 million were recognised as income, compared to DKK 92.2 million in the previous financial year.

Novo Nordisk A/S has in addition provided a restricted donation for the implementation of the Diabetes Compass over the years 2021-2024 of DKK 50 million. This restricted donation is recognised as income as the implementation of the initiative progresses. In 2022, DKK 0.2 million has been recognised as income related to the restricted donation for the Diabetes Compass, compared to DKK 11.7 million in the previous financial year.

Novo Nordisk Foundation grants

In 2022, WDF recognised DKK 73.6 million as income from grants from the Novo Nordisk Foundation compared to DKK 18.7 million in 2021. The income recognised in 2022 relates primarily to the ongoing integrated NCD-humanitarian response in Jordan; the Diabetes Compass programme; the type 1 diabetes care initiative in Eastern Africa and the Middle East; the humanitarian response project with UNHCR (described above); a new country-wide programme in Kenya; and two new pre-grants related to WHO global diabetes compact and innovative social financing models, respectively.

The income from the Novo Nordisk Foundation grants is recognised as the programmes progress.

Government grants

In 2022, WDF received DKK 1.2 million in support of its operational expenses from the Ministry of Culture. In 2021, WDF received a similar contribution of DKK 1.3 million.

Distributions

Pursuant to article 8 of the Statutes of the World Diabetes Foundation, the net profit for the year should, to the widest possible extent, be distributed in the same financial year.

In 2022 WDF made gross distributions of DKK 124.2 million compared to DKK 103.2 million the previous year. Gross distributions thereby exceeded profit for the year by DKK 5.6 million. A number of projects supported in previous years finalised during 2022 and unspent funds from these grants were added to WDF's disposable capital. As a result, WDF's disposable income increased by DKK 1.6 million in 2022 compared to year-end 2021.

Administration

WDF continued to maintain administrative expenses at an acceptable level. WDF is required by its Statutes to keep administrative expenses below 10% of total income. In 2022, administrative expenses were DKK 11.5 million, accounting for 6.7 % of total income, down from 7.5% in the year before.

Fundraising portfolio

In 2022, DKK 1.1 million was raised through various fundraising activities and donations from third parties. 100% of the amount raised will support WDF's 2022 fundraiser project, *Increasing Awareness And Providing Diabetes Care In Vulnerable Communities In Hargeisa, Somaliland*. The project is being rolled out by SOS Children's Village, an international non-governmental organisation that has worked in Somaliland since 1999. It is integrating diabetes into their ongoing Family Strengthening Programming, which is working to improve overall living conditions for internally displaced families in Somaliland. The project will take place over 18 months (2022-23).

In 2022, WDF visited Jordan to see the impact of its 2019 fundraiser project, Prevention and Management of Diabetic Foot for Refugees with Diabetes. Donors raised \$125,000 to fund the project, which was a partnership with the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA). The project strengthened diabetic foot care at 25 UNRWA health centres in Jordan, training 270 healthcare professionals, creating educational materials and acquiring equipment for the clinics, which continue to provide quality diabetes foot care to patients today.

Outlook for 2023

WDF's income is expected to increase by DKK 25 million in 2023 compared to 2022 because of an adjustment to the Donation Agreement with Novo Nordisk A/S, covering until the financial year 2026.

Novo Nordisk A/S has increased the cap of their annual contribution to DKK 119 million in 2023, DKK 120 million in 2024, DKK 121 million in 2025 and DKK 122 million in 2026.

In addition, the outlook can be impacted by the pay-out scheme of grants from the Novo Nordisk Foundation.



An awareness session arranged by WDF's 2022 fundraiser project in Somaliland.



Footcare at a clinic strengthened by WDF's 2019 fundraiser project in Jordan.

GOVERNING PRINCIPLES



A Diabetes Compass workshop in Tanzania.

Quality Assurance

Individual WDF-supported projects are formalised by signing a contract with the local partner, outlining clear milestones, indicators, and criteria for success. Ongoing projects are monitored closely in accordance with WDF’s monitoring system, which includes half-yearly reports, external auditors’ reports, and field visits in the recipient country.

Most projects develop satisfactorily. However, delays do occur; partly in connection with the signing of contracts and start-up; partly in the actual project implementation phase. As instalments are conditional on the achievement of agreed milestones, delays create no significant financial risk for WDF.

Zero tolerance policy

Throughout 2022, WDF institutionalised experience from PwC audits conducted across several selected partnership countries. This serves the dual purpose of building financial and project management capacity within partner organisations and ensuring a high level of accountability and transparency in the administration of supported grants. In countries where PwC audits are not feasible - or where it is not financially appropriate, considering the associated risk and size of project funding, to retain the services of an international audit firm - projects are audited by local audit firms.

WDF systematically reviews and follows up on audit reports, i.e., where internal controls have been found to be inadequate or poor, and where WDF has embargoed release of further project funds until appropriate action plans have been implemented by the recipient organisation.

In the history of WDF, the Board has in a few instances chosen to close a project prematurely due to non-compliance with reporting requirements, or because the applicant institution was unable to meet the terms and conditions of the approved grant.

Long-term commitment

The UN Sustainable Development Goals (SDGs), the World Health Organization (WHO) Global Action Plan (GAP) and national strategies and action plans remain key benchmarks in the realisation of WDF’s mission.

WDF continued its work as official member of the WHO Global Coordinating Mechanism. The Coordinating Mechanism is tasked with supporting the implementation of the SDGs and WHO GAP, including knowledge sharing and coordination with non-state actors and philanthropic foundations. WDF also fully support the roll-out of the Global Diabetes Compact.



Launch of the first NCD strategy for the African continent at African Union headquarters in Addis Ababa.

STATEMENT BY THE MANAGEMENT ON THE ANNUAL REPORT

The Board and Management have today reviewed and adopted the Financial Statements of the World Diabetes Foundation for the financial year 1 January - 31 December 2022. The Financial Statements have been prepared in accordance with the accounting policies described on pages 16 - 17 as well as the Danish Financial Statements Act and Executive Order on financial and administrative contributions to operations grants from the Danish Ministry of Culture. We consider the accounting policies applied appropriate and the estimates made reasonable.

Furthermore, we consider the presentation of the overall Financial Statements to be true and fair. Therefore, in our opinion the Financial Statements give a true and fair view of the financial position, assets, liabilities and the result of the operations of the Foundation.

The undersigned are responsible for fundraising included in the Financial Statement and by signature declare that fundraising has been conducted in accordance with the regulations for fundraising in Denmark.


Bagsværd 16 March 2023

Management



Leif Fenger Jensen

Board of Directors




Anil Kapur
Chairman of the Board



Tina Abild Olesen




Abdallah Daar



Kirstine Brown-Frandsen



Tine Gammeltoft



Kaushik Ramaiya




Christian Holm Jönsson



Peter Haahr



Beneficiaries of WDF's 2022 fundraiser project in Somaliland.



2022 Global Diabetes Walk, Nigeria.

INDEPENDENT AUDITOR'S REPORT

Independent Auditor's report

To the Board of Directors of the World Diabetes Foundation and the Danish Civil Affairs Agency, the authority for non-commercial foundations.

Opinion

In our opinion, the Financial Statements give a true and fair view of the financial position of the Foundation on 31 December 2022, and of the results of the Foundation's operations for the financial year 1 January - 31 December 2022 in accordance with the Danish Financial Statements Act and the Executive Order on financial and administrative contributions to operations grants from the Danish Ministry of Culture.

We have audited the Financial Statements of World Diabetes Foundation for the financial year 1 January - 31 December 2022, which comprise income statement, balance sheet, notes, and summary of significant accounting policies ("financial statements").

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark as well as public auditing standards as the audit is performed on the basis of The Danish Ministry of Culture's Executive Order No 1701 of 21 December 2010 on contributions to operations § 15-20. Our responsibilities under those standards and requirements are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Foundation in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the financial statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, as well as public auditing standards as the audit is performed on the basis of The Danish Ministry of Culture's Executive Order No 1701 of 21 December 2010 on contributions to operations §§ 15-20. Will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, as well as public auditing standards as the audit is performed on the basis of The Danish Ministry of Culture's Executive Order No 1701 of 21 December 2010 on contributions to operations §§ 15-20, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for

INDEPENDENT AUDITOR'S REPORT

one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Bagsværd 16 March 2023

PricewaterhouseCoopers
Statsautoriseret Revisionselskab
CVR no. 33 77 12 31



Jesper Randall Petersen
State Authorised Public Accountant
MNE34352

Report on other legal and regulatory requirements

Additional information required under the Danish Ministry of Culture's Executive Order No 1701 of 21 December 2010.

Statement on compliance audit and performance audit

Management is responsible for the transactions comprised by the financial reporting being in accordance with the contribution to operations received, legislation and other regulations as well as with agreements concluded and generally accepted practice. Management is also responsible for due financial consideration having been shown in the administration of the funds and the operation of the company comprised by the Financial Statements. In this connection, Management is responsible for establishing systems and processes that support economy, productivity and efficiency.

In connection with our audit of the Financial Statements, it is our responsibility to perform a compliance audit and a performance audit of selected subject matters in accordance with public auditing standards. During our compliance audit, we verify with reasonable assurance for the subject matters selected whether the examined transactions comprised by the financial reporting are in accordance with the relevant provisions relating to the contribution to operations received, legislation and other regulations as well as with agreements concluded and generally accepted practice. During our performance audit, we assess with reasonable assurance whether the systems, processes or transactions examined support due financial consideration made in the administration of the funds and the operation of the company comprised by the Financial Statements.

If, on the basis of the work performed, we conclude that our audit gives rise to material critical comments, we are to report on these in this statement.

We do not have any material critical comments to report in this respect.

ACCOUNTING POLICIES

Accounting policies

The financial statements of the World Diabetes Foundation have been prepared in accordance with the Danish Foundation Act as well provisions of the Danish Financial Statements Act applying to reporting class A and Executive Order on financial and administrative contributions to operations grants from the Danish Ministry of Culture and the accounting policies described below.

Translation policies

Assets and liabilities in foreign currencies are translated into Danish kroner at the exchange rates at the balance sheet date, and exchange adjustments are recognised in the profit and loss account. USD bank and currency deposits are used to hedge against accrued distributions in USD. To the extent that the USD deposits are used to hedge against specific liabilities, exchange rate adjustments are recognised for both accrued distributions and for USD deposits in the profit and loss account as financial income and costs.

Tax

According to the Deed of Foundation, the Foundation is required to distribute the entire profit for the year, and therefore no tax is expected for the Foundation. Consequently, no provision has been made for deferred tax on temporary differences in respect of holdings of bonds, as these are eliminated by provisions for future distribution and subsequently offset by a 104% tax value of the deduction in respect of amounts granted by the Foundation.

Recognition of income

Income is calculated on the basis of the following donation programme and extraordinary grant.

Deed of donation

The annual general meeting of Novo Nordisk A/S in 2020 approved a new donation for the financial years 2020 to 2024, which will supersede the remaining five years of the 2014 AGM Donation.

The donation from Novo Nordisk A/S in financial years 2020 to 2024 is calculated as 0.085% of Novo Nordisk's total diabetes care net sales. The Annual Contribution is capped at DKK 91 million in 2020,

increasing one million per year until 2024 or 15% of Novo Nordisk's taxable income, whichever is the lowest in the given financial year.

Donations from Novo Nordisk A/S under the Donation agreement are received every month based on the monthly accounts of the Novo Nordisk Group. Income is recognised when the amounts, which the Foundation has been promised, can be calculated.

Distributions from World Diabetes Foundation

When the World Diabetes Foundation undertakes to support a project by signing a project contract, or in other ways commits itself to making distributions, the amount is recognised in the profit and loss account as a grant included in the profit distribution of the Foundation. No discounting is made of future payments of grants, and it is assumed that the recipients will fulfil all requirements, to be reflected in the form of milestones, for payment of the grants.

Administrative expenses

Total administrative expenses of the Foundation may not exceed 10% of the Foundation's total income. The Foundation's total income is measured as the sum of donations from Novo Nordisk A/S, the Novo Nordisk Foundation and financial income. Administrative expenses include salaries and pensions as well as other administrative expenses in the Foundation's secretariat, remuneration to the Board of Directors, fees to the auditors and to Novo Nordisk A/S and affiliates for various ad hoc services and service level agreement.

Project expenses

Project costs include costs incurred in connection with the monitoring and facilitation of the project portfolio of the Foundation, including salary costs, information material and communication about diabetes in developing countries as well as costs directly related to project coordination with local partners, including authorities, NGOs and companies.

Salary expenses

Salary expenses are split proportionally between administrative expenses and project expenses based on time registration on either administration tasks or project tasks.

ACCOUNTING POLICIES



WDF symposium at the International Diabetes Federation World Diabetes Congress in Lisbon, Portugal.

Receivable with Novo Nordisk A/S

Receivable with Novo Nordisk A/S comprise primarily donations for the last month which the World Diabetes Foundation have been promised, but which have not yet been received.

Accrued distributions

Accrued distributions comprise grants that have not yet been paid, as the milestones have not yet been achieved or as the projects will not be initiated until later, which means that the promise relates to future periods.

Deferred income

Deferred income reflects a restricted upfront payment from Novo Nordisk A/S for a specific initiative to be developed and implemented over the period 2021-2024. Income will be recognised as the project progresses and upon achievement of agreed milestones.

Other liabilities

Other liabilities primarily comprise employee related costs regarding bonus and holiday pay.



Meeting with partners in Jordan.

INCOME STATEMENT

World Diabetes Foundation	NOTE	2022	2021
		DKK '000	DKK '000
Donations from Novo Nordisk A/S and others	1	169,219	124,990
Administration expenses	2, 3	11,574	9,306
Project expenses	2, 4	42,949	23,657
Profit/(loss) before financial income and expenses		114,696	92,027
Financial income	5	4,235	0
Financial expenses	5	396	1,685
Profit/(loss) for the year		118,535	90,342
Proposed distribution			
Distributions for the year before reversals		124,181	103,219
Reversals - completed projects		-7,224	-21,059
Distributions	7	116,957	82,160
At disposal for future distributions		1,578	8,182
		118,535	90,342

BALANCE SHEET AT 31ST DECEMBER

ASSETS

World Diabetes Foundation	NOTE	2022	2021
		DKK '000	DKK '000
Blocked account		260	260
Tied-up assets		260	260
Bank and currency deposits		318,851	291,497
Disposable assets		318,851	291,497
Total assets		319,111	291,757

BALANCE SHEET AT 31ST DECEMBER

LIABILITIES AND EQUITY

World Diabetes Foundation	NOTE	2022	2021
		DKK '000	DKK '000
Tied-up capital		260	260
Disposable capital		19,200	17,622
Total equity	6	19,460	17,882
Trade payables		1,778	206
Accrued distributions	7	230,166	219,509
Deferred income		38,092	38,297
Payable Novo Nordisk A/S		21,433	8,503
Other liabilities		8,182	7,360
Total short-term liabilities		299,651	273,875
Total equity and liabilities		319,111	291,757

NOTES

NOTE 1	Donations received	2022	2021
		DKK '000	DKK '000
	Donation from Novo Nordisk A/S, donation agreement 2020-24 0,085%	93,000	92,245
	Donation from Novo Nordisk A/S, ear-marked for Diabetes Compass	210	11,698
	Donation from Novo Nordisk Foundation	46,934	18,726
	Donation from Novo Nordisk Foundation, ear-marked for Diabetes Compass	26,715	0
	Donation from others	1,111	1,040
	Donation from Ministry of Culture	1,249	1,281
	Total donations	169,219	124,990

NOTE 2	Employee costs	2022	2021
		DKK '000	DKK '000
	Wages and salaries	19,710	17,137
	Pensions	1,843	1,623
	Other employee costs	693	375
	Total employee costs	22,246	19,135
	Average number of employees	26	23

NOTES

NOTE 3 Administration expenses	2022	2021
	DKK '000	DKK '000
Salary costs	7,641	6,841
Remuneration to the Board of Directors	446	447
Rent	262	229
IT & telephony	142	100
Service level agreement with Novo Nordisk A/S and NNIT A/S	134	308
Audit and other accounting services	461	110
Travel expenses	33	2
Stakeholder communications & image building	184	66
Other expenses - Board of Directors	397	0
Translation services	1	16
Other administration expenses	1,873	1,187
Total administration expenses	11,574	9,306
Of the total income of the Foundation, administration expenses amounted to	6.67%	7.45%

NOTES

NOTE 4 Project expenses	2022	2021
	DKK '000	DKK '000
Salary costs	14,605	12,294
Travel expenses	2,063	300
Rent	765	686
Annual review and other publications	0	0
IT & telephony	307	157
Service level agreement with Novo Nordisk A/S and NNIT A/S	780	1,242
Stakeholder communications & image-building	339	263
Other expenses - Board of Directors	29	0
Auditing of local projects	279	79
External cost, Diabetes Compass	20,252	6,892
Other project expenses	3,530	1,744
Total project expenses	42,949	23,657

NOTE 5 Financial income and expenses	2022	2021
	DKK '000	DKK '000
Interest income on bank deposits	2,251	0
Exchange rate gain	1,984	0
Total financial income	4,235	0
Interest expenses	396	969
Exchange rate loss	0	716
Total financial expenses	396	1,685
Net financial items	3,839	-1,685

NOTES

NOTE 6 Equity	2022	2021
	DKK '000	DKK '000
Tied-up capital	260	260
Disposable capital	19,200	17,622
Total equity	19,460	17,882

NOTE 7 Accrued distributions	2022	2021
	DKK '000	DKK '000
Accrued distributions at the beginning of the year	219,509	200,017
Current year distributions	116,957	82,160
Current year payments	-113,963	-72,714
Exchange rate gain/(loss)	7,663	10,046
Accrued distributions at the end of the year	230,166	219,509

Distributions are scheduled to be payable in the periods as follows:

2022	-	138,581
2023	138,582	50,471
2024	55,713	29,356
2025	35,459	551
2026	412	550

Accrued distributions	230,166	219,509
------------------------------	----------------	----------------

NOTE 8 Contingent liabilities

The Foundation has entered into sub-lease and facility management agreements with respectively six and twelve months' notice, equivalent to contingent liabilities of DKK 775k (DKK 753k). Moreover, the Foundation has entered into IT/hosting agreements of 3, 6 and 12 months' notice with a contingent liability of 129k (249k). The Foundation has additional Service Level Agreement expenses with twelve months' notice with a contingent liability of DKK 235k (DKK 169k).

CODE OF CONDUCT

Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease

1. We will recognise people with diabetes and related diseases as dignified humans in all our activities and communications
2. We will display respect for the culture and values of the communities and countries within which we work
3. We will facilitate implementation of the UN Sustainable Development Goals by striving to reduce vulnerability of people served through our grants – addressing basic health needs, promoting equity (in particular gender equity), and fostering sustainable solutions
4. We will give support regardless of race, gender or creed of the recipients in the developing world based upon assessment of needs and capabilities to meet these needs
5. We will promote local ownership of sustainable initiatives in co-operation with governments, private institutions and civil society
6. We will help build and strengthen local capacity to ensure that the recipients, including girls and women, are empowered, as key players in the development process
7. We will seek to support and create synergy between both top-down and bottom-up approaches that apply participation and partnership as both a means and a goal
8. We will be accountable to both those we seek to assist and those from whom we accept resources
9. We will adopt and require our partners to adopt a zero tolerance policy to corruption and bribery
10. We will be open and transparent, and report on the impact of our work, and the factors limiting or enhancing that impact



The World Diabetes Foundation is a leading global funder of diabetes prevention and care projects in low- and middle-income countries.

Our vision is to alleviate human suffering related to diabetes among those in greatest need.

We support projects that are demand-driven, locally formulated and owned, and integrated into existing health systems where possible and pursue sustainable, scalable approaches, helping countries meet global goals for improved care of diabetes and other non-communicable diseases.

